Advanced kidney cancer

The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within...


Initial results from the phase 1 clinical trial EV-103 were announced. Forty-five patients were evaluated for safety with the combination...


The European Commission ( EC ) has approved Bavencio ( Avelumab ) in combination with Axitinib ( Inlyta ) for...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Balversa ( Erdafitinib ), a treatment...


The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta (...


The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...


A combination of the immune checkpoint blocker, Avelumab ( Bavencio ), plus the tyrosine kinase inhibitor ( TKI ),...


New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder,...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...


The FDA ( U.S. Food and Drug Administration ) has approved Lutathera ( Lutetium Lu 177 dotatate ) for the...


In a letter published in the cancer journal Annals of Oncology, researchers led by Jean-Philippe Spano, at Pitie-Salpetriere Hospital AP-HP...


The European Commission ( EC ) has approved Fotivda ( Tivozanib ) for the treatment of adult patients with advanced...




Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced...


Lenvatinib mesylate ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel...


The U.S. Food and Drug Administration ( FDA ) has approved an additional indication for Lenvima ( Lenvatinib mesylate )...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...